Omrix' vascular sealant:
This article was originally published in Clinica
The US FDA has given Omrix Biopharmaceuticals the all-clear to expand the market for its Evicel haemostat to use in vascular surgery. The liquid fibrin sealant, which was previously approved for use in liver surgery, can now also be marketed to peripheral vascular surgeons, cardiac surgeons, plastic surgeons performing microvascular anastomoses, transplant surgeons, and trauma surgeons performing vascular repair. The Kiryat Ono, Israel firm believes that the vascular surgery market is approximately twice the size of the liver surgery market. It also expects to gain a general haemostasis in surgery indication for Evicel in the first quarter of 2008. Evicel is marketed by Ethicon, a Johnson & Johnson company.
You may also be interested in...
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.